Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked atreal-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments.

This Plain Language Summary of Publication from Neurodegenerative Disease Management summarises results from the MSBase registry. The MSBase registry contains information from over

80,000 people living with multiple sclerosis (MS). Using this information a study called GLIMPSE was carried out. The study found real-life outcomes in people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments.

Read the full article here.

The original article on which this summary is based was published in Multiple Sclerosis Journal. The original article is called ‘Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry’. You can read it here.